No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
VTR Ventas Inc
- 42.640
- +0.410+0.97%
Close Apr 18 16:00 ET
17.23BMarket Cap-426400P/E (TTM)
42.840High42.045Low1.86MVolume42.340Open42.230Pre Close79.32MTurnover0.46%Turnover RatioLossP/E (Static)404.05MShares50.08352wk High1.82P/B17.13BFloat Cap38.58052wk Low1.80Dividend TTM401.85MShs Float61.550Historical High4.22%Div YieldTTM1.88%Amplitude0.690Historical Low42.623Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | NYSE Order Imbalance 66883.0 Shares on Sell Side 66883.0 Shares on Sell Side
Land & Buildings Issues Letter to Shareholders of National Health Investors Announcing Its Intention to Vote Against Two Directors at 2024 Annual Meeting
Believes NHI is Significantly Undervalued with Opportunities to Unlock its Valuable Assets, Including Upcoming Lease Renewal with Tenant National Healthcare Corporation Highlights Poor Corporate Governance and Serious
Express News | NYSE Order Imbalance 79586.0 Shares on Buy Side
Short Interest on S&P 500 Real Estate Stocks Advance in March
Express News | Ventas Inc : Jefferies Cuts Target Price to $52 From $57
Is It Wise to Retain Ventas (VTR) Stock in Your Portfolio?
Comments
Analyst Connor Siversky predicts OHI and NHI's rent coverage will increase due to improving portfolio metrics. However, he doubts VTR's senior housing portfolio improvement will offset high leverage and limited investment opportunities. He also suggests OHI's dividend will be covered in late 2024, and NHI is set to drive growth with a strong liquidity profile.
Omega Healthcare, National Health Investors Upgraded to Overweight at Wells Fargo 1
TOP WATCH 7/3 ⚡️⚡️
follow for daily top watchlist ⭐️
$Apyx Medical(APYX.US$$Addentax(ATXG.US$$Axsome Therapeutics(AXSM.US$$BioXcel Therapeutics(BTAI.US$$Baudax Bio(BXRX.US$$CymaBay Therapeutics(CBAY.US$$CorMedix(CRMD.US$$Marriott International(MAR.US$$Microvision(MVIS.US$$Renalytix(RNLX.US$$State Street(STT.US$$Treehouse Foods(THS.US$$Targa Resources(TRGP.US$$VBI Vaccines(VBIV.US$$Ventas Inc(VTR.US$
$Apyx Medical(APYX.US$$Addentax(ATXG.US$$Axsome Therapeutics(AXSM.US$$BioXcel Therapeutics(BTAI.US$$Baudax Bio(BXRX.US$$CymaBay Therapeutics(CBAY.US$$CorMedix(CRMD.US$$Marriott International(MAR.US$$Microvision(MVIS.US$$Renalytix(RNLX.US$$State Street(STT.US$$Treehouse Foods(THS.US$$Targa Resources(TRGP.US$$VBI Vaccines(VBIV.US$$Ventas Inc(VTR.US$
1
ColumnsUS Top Rating Updates on 6/23: EVO, VTR, UAA, AFRM and More
$Affirm Holdings(AFRM.US$ initiated at neutral by Compass Point, announced target price at $15.00.
$SoFi Technologies(SOFI.US$ initiated at sell by Compass Point, announced targe price at $5.00.
$Evotec(EVO.US$ was upgraded by Morgan Stanley from equal-weight to overweight, increased target price from $12.00 to $16.00.
$Principal Financial(PFG.US$ was upgraded by Jefferies from underperform to hold, increased target price from $60.00 to $6...
$SoFi Technologies(SOFI.US$ initiated at sell by Compass Point, announced targe price at $5.00.
$Evotec(EVO.US$ was upgraded by Morgan Stanley from equal-weight to overweight, increased target price from $12.00 to $16.00.
$Principal Financial(PFG.US$ was upgraded by Jefferies from underperform to hold, increased target price from $60.00 to $6...
15
ColumnsTop upgrades and downgrades on 6/30: AMD, U, BG, CPNG and more
Upgrades
• $Advanced Micro Devices(AMD.US$ : Northland Capital Upgrades to Outperform from Market Perform - PT $95
• $Bunge(BG.US$ : BofA Securities Upgrades to Buy from Neutral - PT $135 (from $140)
•$Brookfield Infrastructure Partners LP(BIP.US$ : Credit Suisse Upgrades to Outperform from Neutral - PT $49.50
• $Banco Santander Chile(BSAC.US$ : UBS Upgrades to Neutral from Sell - PT $18 (from $17)
• $Crown Castle(CCI.US$ : Jefferi...
• $Advanced Micro Devices(AMD.US$ : Northland Capital Upgrades to Outperform from Market Perform - PT $95
• $Bunge(BG.US$ : BofA Securities Upgrades to Buy from Neutral - PT $135 (from $140)
•$Brookfield Infrastructure Partners LP(BIP.US$ : Credit Suisse Upgrades to Outperform from Neutral - PT $49.50
• $Banco Santander Chile(BSAC.US$ : UBS Upgrades to Neutral from Sell - PT $18 (from $17)
• $Crown Castle(CCI.US$ : Jefferi...
18
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
